Las Vegas, USA, Oct. 27, 2021 (GLOBE NEWSWIRE) -- DelveInsight Analyzes a Thriving Cutaneous Lupus Erythematosus Pipeline in the Coming Years as Key Pharma Companies Enter the Sphere
The Cutaneous Lupus Erythematosus Pipeline is flourishing with novel treatment agents targeted to meet the unmet need in the Cutaneous Lupus Erythematosus treatment domain.
DelveInsight’s ‘Cutaneous Lupus Erythematosus Pipeline Insight 2021’ report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Cutaneous Lupus Erythematosus pipeline domain.
Some of the salient features from the Cutaneous Lupus Erythematosus Pipeline report:
- DelveInsight’s Cutaneous Lupus Erythematosus Pipeline analysis depicts the space with 10+ active players working to develop 10+ pipeline therapies.
- Major pharmaceutical companies are developing potential drug candidates to improve the Cutaneous Lupus Erythematosus treatment scenario, such as Hoth Therapeutics, Centessa Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Sanofi, Zylo Therapeutics, Galapagos, Gilead Sciences, Viela Bio, Rigel Pharmaceuticals, AstraZeneca, and others.
- Key Cutaneous Lupus Erythematosus pipeline therapies such as HT-005, CBS004, BMS-986256, M5049, BMS-986165 (deucravacitinib), BIIB059, SAR443122, and others are under investigation in different phases of clinical trials.
- In June 2021, Denali Therapeutics announced that its partner Sanofi had commenced dosing in a Phase II study of DNL758 (SAR443122), a peripherally-restricted small molecule inhibitor of RIPK1, in patients with Cutaneous Lupus Erythematosus (CLE).
Request for Sample to know which pharma company is anticipated to take charge of Cutaneous Lupus Erythematosus pipeline in the forthcoming years @ Cutaneous Lupus Erythematosus Forecast
The Cutaneous Lupus Erythematosus pipeline report lays down detailed profiles of the pipeline assets, inactive and dormant assets, comparative analysis of clinical and non-clinical stage Cutaneous Lupus Erythematosus products, comprehensive assessment of driving and restraining factors, along with the opportunities and risks in the Cutaneous Lupus Erythematosus pipeline landscape.
Cutaneous Lupus Erythematosus Overview
Cutaneous Lupus Erythematosus is an autoimmune disease that can present as isolated skin disease or as a manifestation within the spectrum of systemic lupus erythematosus. Cutaneous Lupus Erythematosus can occur as a manifestation of systemic lupus erythematosus (SLE) or independent of SLE.
The clinical spectrum of Cutaneous Lupus Erythematosus is broad, ranging from isolated discoid plaques to widespread skin lesions. Acute Cutaneous Lupus Erythematosus typically presents as transient erythematous patches associated with a flare of systemic lupus erythematosus.
Discover more about the disease, treatments, and pipeline therapies @ Cutaneous Lupus Erythematosus Pipeline Assessment
Cutaneous Lupus Erythematosus Pipeline Drugs
| Drug | Company | Phase | MoA | RoA |
| HT-005 | Hoth Therapeutics | Preclinical | Cannabinoid receptor CB1, CB2 agonists | Topical |
| CBS004 | Centessa Pharmaceuticals | Preclinical | CLEC4C protein inhibitors | Parenteral |
| BMS-986256 | Bristol-Myers Squibb | Phase I | Toll-like receptor 7,8 antagonists | NA |
| M5049 | Merck | Phase I | Toll-like receptor 7,8 antagonists | Oral |
| BMS-986165 | Bristol-Myers Squibb | Phase II | TYK2 kinase inhibitors | NA |
| BIIB059 | Biogen | Phase II | CLEC4C protein inhibitors | Subcutaneous |
| SAR443122 | Sanofi | Phase II | RIPK1 protein inhibitors | Oral |
Request for Sample to get an overview of the pipeline landscape @ Cutaneous Lupus Erythematosus Pipeline Analysis
Cutaneous Lupus Erythematosus Therapeutics Assessment
The Cutaneous Lupus Erythematosus Pipeline report proffers an integral view of the Cutaneous Lupus Erythematosus emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.
By Product Type
- Mono
- Combination
- Mono/Combination
By Stage
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
By Route of Administration
- Subcutaneous
- Intravenous
- Oral
- Parenteral
- Topical
By Molecule Type
- Cannabinoids
- Monoclonal antibodies
- Arachidonic acids
- Small molecules
By Mechanism of Action
- Cannabinoid receptor CB1, CB2 agonists
- CLEC4C protein inhibitors
- Toll-like receptor 7,8 antagonists
- TYK2 kinase inhibitors
- RIPK1 protein inhibitors
Scope of the Cutaneous Lupus Erythematosus Pipeline Report
- Coverage: Global
- Major Players: Hoth Therapeutics, Centessa Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Sanofi, Zylo Therapeutics, Galapagos, Gilead Sciences, Viela Bio, Rigel Pharmaceuticals, AstraZeneca, and others
- Key Cutaneous Lupus Erythematosus Pipeline Therapies: HT-005, CBS004, BMS-986256, M5049, BMS-986165 (deucravacitinib), BIIB059, SAR443122, and others
For rich insights into emerging therapies and assessment, visit @ Cutaneous Lupus Erythematosus Emerging Novel Therapies
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Cutaneous Lupus Erythematosus: Overview |
| 4 | Pipeline Therapeutics |
| 5 | Cutaneous Lupus Erythematosus: Late Stage Products (Pre-registration) |
| 6 | Cutaneous Lupus Erythematosus: Late Stage Products (Phase III) |
| 7 | Cutaneous Lupus Erythematosus: Mid Stage Products (Phase II) |
| 8 | Cutaneous Lupus Erythematosus: Early Stage Products (Phase I) |
| 9 | Pre-clinical and Discovery Stage Products |
| 10 | Therapeutic Assessment Cutaneous Lupus Erythematosus |
| 11 | Inactive Products Cutaneous Lupus Erythematosus |
| 12 | Cutaneous Lupus Erythematosus - Unmet Needs |
| 13 | Cutaneous Lupus Erythematosus - Market Drivers and Barriers |
| 14 | Appendix |
| 15 | About DelveInsight |
Get a customized pipeline report @ Cutaneous Lupus Erythematosus Ongoing Clinical Trials
Track and assess a candidate’s clinical development journey through Comparative Therapeutic Assessment
Related Reports
Cutaneous Lupus Erythematosus Market
DelveInsight's "Cutaneous Lupus Erythematosus - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology, market drivers, market barriers and key companies included like Centessa Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Sanofi, Zylo Therapeutics, Galapagos, Gilead Sciences, Viela Bio, Rigel Pharmaceuticals, and others.
Systemic Lupus Erythematosus Market
DelveInsight’s ‘Systemic Lupus Erythematosus - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Systemic Lupus Erythematosus, historical and forecasted epidemiology, market drivers, market barriers and key companies involved like GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Biogen, UCB Pharma, Immupharma, Hoffmann-La Roche, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer and many others.
DelveInsight’s ‘Psoriatic Arthritis (PsA)– Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the historical and forecasted epidemiology profiling of pipeline therapeutics, ongoing clinical trials, key cross competition, and key pharmaceuticals involved like AbbVie, Amgen/Pfizer, Bristol-Myers Squibb, Janssen Biotech, Amgen, Eli Lilly and Company, Pfizer, UCB, Bristol-Myers Squibb, Sun Pharma Global FZE, and many others.
DelveInsight’s, “RIPK1 inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in RIPK1 inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment, and key companies involved such as Denali Therapeutics, Sanofi, Voronoi, GenFleet Therapeutics, GlaxoSmithKline, and several others.
TYK2 Kinase Inhibitors Pipeline
DelveInsight’s, “TYK2 Kinase Inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TYK2 Kinase Inhibitors pipeline landscape. It covers the pipeline drug profiles, pipeline products in this space and key companies involved such as Incyte Corporation, Bristol-Myers Squibb, Oncostellae, Pfizer, Galapagos, Haisco Pharmaceutical Group, Sareum, Oncostellae, and several others.
DelveInsight's "Friedreich's Ataxia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Friedreich's Ataxia, historical and forecasted epidemiology as well as market share of the individual therapies, current and forecasted Friedreich's Ataxia market Size treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Cutaneous Lupus Erythematosus Epidemiology
DelveInsight's 'Cutaneous Lupus Erythematosus (CLE) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Cutaneous Lupus Erythematosus (CLE) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Browse Through Our Blog Posts
Systemic Lupus Erythematosus Market: How the Leading Companies are Countering the Rising Prevalence?
Systemic Lupus Erythematosus is a chronic inflammatory disease that affects connective tissues such as cartilage and blood vessel lining, which provide strength and flexibility to body structures.
Aurinia’s Lupkynis for Lupus
Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis.
Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies
As per the American Autoimmune Related Diseases Association (AARDA), nearly 50 million people in the USA are affected by autoimmune diseases such as rheumatoid arthritis, psoriasis, and lupus.
Pipeline Assessment revolving around client’s area of interest supporting strategic decisions
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
